N

Minerva Neurosciences
D

NERV

2.27000
USD
0.46
(25.41%)
مغلق
حجم التداول
1,750
الربح لكل سهم
-3
العائد الربحي
-
P/E
3
حجم السوق
15,875,032
أصول ذات صلة
A
ANVS
-0.00500
(-0.18%)
2.72500 USD
C
CRVS
0.57000
(11.74%)
5.42500 USD
C
CYCC
-0.97000
(-10.95%)
7.89000 USD
M
MGTX
-0.13000
(-1.56%)
8.18000 USD
NTRA
NTRA
4.540
(2.86%)
163.020 USD
X
XNCR
0.04000
(0.52%)
7.68500 USD
المزيد
الأخبار المقالات

العنوان: Minerva Neurosciences

القطاع: Healthcare
الصناعة: Biotechnology
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.